Opus Genetics (IRD) Stock Statistics & Valuation Metrics

Opus Genetics has a market cap or net worth of $390.70M. The enterprise value is $356.67M.

Opus Genetics has 81,395,540 shares outstanding. The number of shares has decreased by -2.65% in one year.

Opus Genetics’s return on equity (ROE) is -3.23 and return on invested capital (ROIC) is -90.90%.

The current PE Ratio of Opus Genetics is ―. Opus Genetics’s PEG ratio is 0.40.

In the last 12 months, Opus Genetics had revenue of 14.20M and earned -49.59M in profits. Earnings per share was -0.80.

In the last 12 months, operating cash flow was -38.99M and capital expenditures 0.00, giving a free cash flow of -38.99M billion.

Opus Genetics pays an annual dividend of ―, resulting in a dividend yield of ―

Opus Genetics upcoming earnings date is Aug 7, 2026, After Close (Confirmed).

Opus Genetics as a current ratio of 6.43, with Debt / Equity ratio of -56.58%

In the past 12 months, Opus Genetics has paid 0.00 in taxes.

Opus Genetics EV to EBITDA ratio is -25.08, with an EV/FCF ratio of -34.20.

Opus Genetics has $59.96M in cash and marketable securities with $25.93M in debt, giving a net cash position of $34.02M billion.

Gross margin is 49.64%, with operating margin of -271.90%, and net profit margin of -349.33%.

The average price target for Opus Genetics is $10.58, which is 11.43% higher than the current price. The consensus rating is Strong Buy